Literature DB >> 10921391

Natural history of hepatitis C virus infection.

D Amarapurkar1.   

Abstract

Hepatitis C is a heterogeneous disease whose natural history is controversial and perplexing. However, it can be a pernicious disease and is responsible for considerable mortality and morbidity. More than 80% individuals infected with the hepatitis C virus (HCV) develop chronic infection; the remaining 10-20% develop spontaneous clearance with natural immunity. The majority of patients who develop chronic HCV infection are asymptomatic; but 60-80% develop chronic hepatitis as indicated by elevated ALT; around 30% maintain normal ALT. One-third of chronically infected patients develop progressive liver injury, fibrosis and cirrhosis over a period of 20-30 years, and 15% develop hepatocellular carcinoma. Acquiring infection after the age of 40 years, male sex, excessive alcohol-consumption, HBV or HIV co-infection and the immunosuppressive state have been identified as factors associated with progression of fibrosis and development of cirrhosis. The relationship between virus load, HCV genotype I and quasispecies variability and progression of live disease is controversial. In the present study on 141 patients with chronic HCV infection and established chronic liver disease, the median time to develop cirrhosis was 20 years. Progression to cirrhosis was faster (16 vs 20 years) in those who acquired infection after the age of 35 years, and in immunosuppressed patients (8 vs 21 years), whereas diabetes, sex and HBV co-infection were not associated with faster progression.

Entities:  

Mesh:

Year:  2000        PMID: 10921391     DOI: 10.1046/j.1440-1746.2000.02110.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  12 in total

1.  Liver transplantation for hepatocellular carcinoma.

Authors:  A W Hemming; M S Cattral; A I Reed; W J Van Der Werf; P D Greig; R J Howard
Journal:  Ann Surg       Date:  2001-05       Impact factor: 12.969

2.  Most Patients of Hepatitis C Virus Infection in India Present Late for Interferon-Based Antiviral Treatment: An Epidemiological Study of 777 Patients from a North Indian Tertiary Care Center.

Authors:  Varun Gupta; Ashish Kumar; Praveen Sharma; Naresh Bansal; Vikas Singla; Anil Arora
Journal:  J Clin Exp Hepatol       Date:  2015-05-21

3.  Transmission of hepatitis C virus in a gynecological surgery setting.

Authors:  M Massari; N Petrosillo; G Ippolito; L Solforosi; L Bonazzi; M Clementi; A Manzin
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

Review 4.  Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part I: Status Report of HCV Infection in India.

Authors:  Pankaj Puri; Anil C Anand; Vivek A Saraswat; Subrat K Acharya; Radha K Dhiman; Rakesh Aggarwal; Shivram P Singh; Deepak Amarapurkar; Anil Arora; Mohinish Chhabra; Kamal Chetri; Gourdas Choudhuri; Vinod K Dixit; Ajay Duseja; Ajay K Jain; Dharmesh Kapoorz; Premashis Kar; Abraham Koshy; Ashish Kumar; Kaushal Madan; Sri P Misra; Mohan V G Prasad; Aabha Nagral; Amarendra S Puri; R Jeyamani; Sanjiv Saigal; Shiv K Sarin; Samir Shah; P K Sharma; Ajit Sood; Sandeep Thareja; Manav Wadhawan
Journal:  J Clin Exp Hepatol       Date:  2014-06-09

5.  Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation.

Authors:  Nestor F Esnaola; Gregory Y Lauwers; Nadeem Q Mirza; David M Nagorney; Dorota Doherty; Iwao Ikai; Yoshio Yamaoka; Jean Marc Regimbeau; Jacques Belghiti; Steven A Curley; Lee M Ellis; J Nicolas Vauthey
Journal:  J Gastrointest Surg       Date:  2002 Mar-Apr       Impact factor: 3.452

6.  Predictors of alcohol use among rural drug users after disclosure of hepatitis C virus status.

Authors:  Dustin B Stephens; Jennifer R Havens
Journal:  J Stud Alcohol Drugs       Date:  2013-05       Impact factor: 2.582

7.  State of the Globe: Helicobacter pylori and Hepatitis C Together Hamper Health.

Authors: 
Journal:  J Glob Infect Dis       Date:  2010-01

8.  Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study.

Authors:  Shannon Allen Ferrante; Jagpreet Chhatwal; Clifford A Brass; Antoine C El Khoury; Fred Poordad; Jean-Pierre Bronowicki; Elamin H Elbasha
Journal:  BMC Infect Dis       Date:  2013-04-27       Impact factor: 3.090

9.  How can we reduce the burden of Hepatitis C?

Authors:  Deepak Amarapurkar
Journal:  Saudi J Gastroenterol       Date:  2011 Jul-Aug       Impact factor: 2.485

10.  Comparison of quasispecies diversity of HCV between chronic hepatitis c and hepatocellular carcinoma by Ultradeep pyrosequencing.

Authors:  Chang-Wook Park; Min-Chul Cho; Keumrock Hwang; Sun-Young Ko; Heung-Bum Oh; Han Chu Lee
Journal:  Biomed Res Int       Date:  2014-06-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.